Back Hepatitis C

Hepatitis C

Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C

Achillion Pharmaceuticalsannounced this week that the first participants have started receiving treatment in a Phase 1 clinical trial testing the investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor ACH-3422. In addition, a recently initiated Phase 2 study is evaluating the company's next-generation NS5A inhibitor ACH-3012 in combination with Gilead Sciences' sofosbuvir (Sovaldi) for as little as 8 or even 6 weeks.

alt

EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most problematic symptoms associated with chronic hepatitis C, according to research presented at the EASL Liver International Liver Congressthis month in London.

alt

EASL 2014: Researchers Look at Treatment as Prevention for Hepatitis C

Widespread hepatitis C treatment with effective new direct-acting antivirals could dramatically reduce hepatitis C virus (HCV) transmission, but making this work on a large scale will require efforts to scale up HCV screening and bring down drug costs, according to several presentations at the EASL International Liver Congress this month in London.

alt

EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4

A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat  hepatitis C virus (HCV) genotype 4, though treatment for only 12 weeks was not as effective, according to a poster presentation at the EASL International Liver Congress this month in London.

alt

EASL 2014: Sofosbuvir Works Well Despite Multiple Negative Predictive Factors

Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having 4 or more negative predictive factors, however, raises the risk of post-treatment relapse, according to a report at the 49th EASL International Liver Congress held recently in London.alt

AbbVie Requests FDA Approval of Interferon-free "3D" Combo for Hepatitis C

AbbVie announced this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval of its "3D" regimen of direct-acting antivirals -- ABT-450/ritonavir, ombitasvir (ABT-267), and dasabuvir (ABT-333), to be used with or without ribavirin. 3D has been designated as an FDA "breakthrough therapy" and an approval decision is expected by the end of the year.

alt

AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence

A 3-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C virus (HCV) in a small Phase 2 study reported last week at the 49th EASL International Liver Congress (EASL 2014) in London.

alt

EASL 2014: Kaiser Study Examines Who Receives Hepatitis C Treatment

Most people with chronic hepatitis C in the Kaiser Southern California health plan have not received treatment, often due to co-existing conditions and contraindications, but practice is evolving with the approval of more effective and better tolerated direct-acting antivirals, according to a study presented at the 49thEASL International Liver Congress this month in London.

alt

EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6

A new experimental NS5A inhibitor, GS-5816, was shown to be safe and effective when used in an interferon- and ribavirin-free dual regimen with sofosbuvir (Sovaldi) for people with hepatitis C genotypes 1 through 6, according to Phase 2 results presented at the 49thEASL International Liver Congress last week in London.

alt